Artwork

Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

🧪🛡️ Stroke Shield: How Tirofiban Tips the Scales

3:14
 
Share
 

Manage episode 493334231 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

🧠✨ New Stroke Breakthrough!

The ASSET-IT trial shows that early infusion of tirofiban after thrombolysis significantly boosts recovery in noncardioembolic stroke patients — with 65.9% achieving excellent outcomes at 90 days vs 54.9% with placebo 📈💉

✅ Improved function

⚠️ Slightly higher bleeding risk

🌏 Study conducted across 38 centers in China

📚 Read the trial in NEJM (July 2025)

#Stroke #Tirofiban #Neurology #RCT #PrecisionMedicine #Thrombolysis #CardiovascularResearch

  continue reading

564 episodes

Artwork
iconShare
 
Manage episode 493334231 series 2740117
Content provided by MasterMedFacts LLC and RR Baliga MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC and RR Baliga MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

🧠✨ New Stroke Breakthrough!

The ASSET-IT trial shows that early infusion of tirofiban after thrombolysis significantly boosts recovery in noncardioembolic stroke patients — with 65.9% achieving excellent outcomes at 90 days vs 54.9% with placebo 📈💉

✅ Improved function

⚠️ Slightly higher bleeding risk

🌏 Study conducted across 38 centers in China

📚 Read the trial in NEJM (July 2025)

#Stroke #Tirofiban #Neurology #RCT #PrecisionMedicine #Thrombolysis #CardiovascularResearch

  continue reading

564 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play